칸나비디올 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "칸나비디올" in Korean language version.

refsWebsite

Global rank Korean rank

10doi.org

2^nd place

3^rd place

10nih.gov

4^th place

2fda.gov

447^th place

433^rd place

1ebi.ac.uk

5,849^th place

955^th place

1web.archive.org

1^st place

1bayer.ca

low place

1worldcat.org

5^th place

11^th place

1cnbc.com

220^th place

358^th place

1marijuanamoment.net

low place

bayer.ca

omr.bayer.ca

“Sativex (Cannabidiol/Tetrahydrocannabinol) Bayer Label” (PDF). 《bayer.ca》. 2021년 1월 16일에 원본 문서 (PDF)에서 보존된 문서. 2018년 6월 28일에 확인함.

cnbc.com

“DEA reschedules Epidiolex, marijuana-derived drug, paving the way for it to hit the market”. CNBC. 2018년 9월 27일.

doi.org

dx.doi.org

Mechoulam R, Parker LA, Gallily R (November 2002). “Cannabidiol: an overview of some pharmacological aspects”. 《Journal of Clinical Pharmacology》 42 (11 Suppl): 11S–19S. doi:10.1002/j.1552-4604.2002.tb05998.x. PMID 12412831.
Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (May 2009). “Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders”. 《Phytotherapy Research》 (Review) 23 (5): 597–602. doi:10.1002/ptr.2625. PMID 18844286.
Devinsky, Orrin; Cilio, Maria Roberta; Cross, Helen; Fernandez-Ruiz, Javier; French, Jacqueline; Hill, Charlotte; Katz, Russell; Di Marzo, Vincenzo; Jutras-Aswad, Didier; Notcutt, William George; Martinez-Orgado, Jose; Robson, Philip J.; Rohrback, Brian G.; Thiele, Elizabeth; Whalley, Benjamin; Friedman, Daniel (2014년 5월 22일). “Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders”. 《Epilepsia》 55 (6): 791–802. doi:10.1111/epi.12631. PMC 4707667. PMID 24854329.
Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS (December 2012). “Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders”. 《Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences》 (Review) 367 (1607): 3364–78. doi:10.1098/rstb.2011.0389. PMC 3481531. PMID 23108553.
Boggs, Douglas L; Nguyen, Jacques D; Morgenson, Daralyn; Taffe, Michael A; Ranganathan, Mohini (2017년 9월 6일). “Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol”. 《Neuropsychopharmacology》 43 (1): 142–154. doi:10.1038/npp.2017.209. ISSN 0893-133X. PMC 5719112. PMID 28875990.
Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M (July 2017). “Cannabidiol: State of the art and new challenges for therapeutic applications”. 《Pharmacol. Ther.》 175: 133–150. doi:10.1016/j.pharmthera.2017.02.041. PMID 28232276.
Iseger TA, Bossong MG (March 2015). “A systematic review of the antipsychotic properties of cannabidiol in humans”. 《Schizophrenia Research》 162 (1–3): 153–61. doi:10.1016/j.schres.2015.01.033. PMID 25667194.
Aizpurua-Olaizola O, Soydaner U, Öztürk E, Schibano D, Simsir Y, Navarro P, Etxebarria N, Usobiaga A (February 2016). “Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes”. 《Journal of Natural Products》 79 (2): 324–31. doi:10.1021/acs.jnatprod.5b00949. PMID 26836472.
Laun AS, Shrader SH, Brown KJ, Song ZH (June 2018). “GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol”. 《Acta Pharmacol. Sin.》 40 (3): 300–308. doi:10.1038/s41401-018-0031-9. PMID 29941868.
Taura F, Sirikantaramas S, Shoyama Y, Yoshikai K, Shoyama Y, Morimoto S (June 2007). “Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa”. 《FEBS Letters》 581 (16): 2929–34. doi:10.1016/j.febslet.2007.05.043. PMID 17544411.

ebi.ac.uk

https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:69478

fda.gov

accessdata.fda.gov

“Epidiolex (Cannabidiol) FDA Label” (PDF). 《fda.gov》. 2018년 6월 28일에 확인함. For label updates see FDA index page for NDA 210365

fda.gov

“FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy”. US Food and Drug Administration. 2018년 6월 25일. 2018년 6월 25일에 확인함.

marijuanamoment.net

Angell T (2018년 8월 13일). “UN Launches First-Ever Full Review Of Marijuana’s Status Under International Law”. 《Marijuana Moment》. 2018년 11월 1일에 확인함.

nih.gov

ncbi.nlm.nih.gov

Mechoulam R, Parker LA, Gallily R (November 2002). “Cannabidiol: an overview of some pharmacological aspects”. 《Journal of Clinical Pharmacology》 42 (11 Suppl): 11S–19S. doi:10.1002/j.1552-4604.2002.tb05998.x. PMID 12412831.
Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (May 2009). “Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders”. 《Phytotherapy Research》 (Review) 23 (5): 597–602. doi:10.1002/ptr.2625. PMID 18844286.
Devinsky, Orrin; Cilio, Maria Roberta; Cross, Helen; Fernandez-Ruiz, Javier; French, Jacqueline; Hill, Charlotte; Katz, Russell; Di Marzo, Vincenzo; Jutras-Aswad, Didier; Notcutt, William George; Martinez-Orgado, Jose; Robson, Philip J.; Rohrback, Brian G.; Thiele, Elizabeth; Whalley, Benjamin; Friedman, Daniel (2014년 5월 22일). “Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders”. 《Epilepsia》 55 (6): 791–802. doi:10.1111/epi.12631. PMC 4707667. PMID 24854329.
Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS (December 2012). “Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders”. 《Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences》 (Review) 367 (1607): 3364–78. doi:10.1098/rstb.2011.0389. PMC 3481531. PMID 23108553.
Boggs, Douglas L; Nguyen, Jacques D; Morgenson, Daralyn; Taffe, Michael A; Ranganathan, Mohini (2017년 9월 6일). “Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol”. 《Neuropsychopharmacology》 43 (1): 142–154. doi:10.1038/npp.2017.209. ISSN 0893-133X. PMC 5719112. PMID 28875990.
Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M (July 2017). “Cannabidiol: State of the art and new challenges for therapeutic applications”. 《Pharmacol. Ther.》 175: 133–150. doi:10.1016/j.pharmthera.2017.02.041. PMID 28232276.
Iseger TA, Bossong MG (March 2015). “A systematic review of the antipsychotic properties of cannabidiol in humans”. 《Schizophrenia Research》 162 (1–3): 153–61. doi:10.1016/j.schres.2015.01.033. PMID 25667194.
Aizpurua-Olaizola O, Soydaner U, Öztürk E, Schibano D, Simsir Y, Navarro P, Etxebarria N, Usobiaga A (February 2016). “Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes”. 《Journal of Natural Products》 79 (2): 324–31. doi:10.1021/acs.jnatprod.5b00949. PMID 26836472.
Laun AS, Shrader SH, Brown KJ, Song ZH (June 2018). “GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol”. 《Acta Pharmacol. Sin.》 40 (3): 300–308. doi:10.1038/s41401-018-0031-9. PMID 29941868.
Taura F, Sirikantaramas S, Shoyama Y, Yoshikai K, Shoyama Y, Morimoto S (June 2007). “Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa”. 《FEBS Letters》 581 (16): 2929–34. doi:10.1016/j.febslet.2007.05.043. PMID 17544411.

web.archive.org

“Sativex (Cannabidiol/Tetrahydrocannabinol) Bayer Label” (PDF). 《bayer.ca》. 2021년 1월 16일에 원본 문서 (PDF)에서 보존된 문서. 2018년 6월 28일에 확인함.

worldcat.org

Boggs, Douglas L; Nguyen, Jacques D; Morgenson, Daralyn; Taffe, Michael A; Ranganathan, Mohini (2017년 9월 6일). “Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol”. 《Neuropsychopharmacology》 43 (1): 142–154. doi:10.1038/npp.2017.209. ISSN 0893-133X. PMC 5719112. PMID 28875990.